Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2018’, provides an overview of the Chagas Disease (American Trypanosomiasis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chagas Disease (American Trypanosomiasis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chagas Disease (American Trypanosomiasis)

- The report reviews pipeline therapeutics for Chagas Disease (American Trypanosomiasis) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Chagas Disease (American Trypanosomiasis) therapeutics and enlists all their major and minor projects

- The report assesses Chagas Disease (American Trypanosomiasis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Chagas Disease (American Trypanosomiasis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chagas Disease (American Trypanosomiasis)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chagas Disease (American Trypanosomiasis) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AstraZeneca Plc

Bayer AG

Daiichi Sankyo Co Ltd

Eisai Co Ltd

Evotec AG

GlaxoSmithKline Plc

Grupo Praxis Pharmaceutical SA

Kancera AB

Novartis AG

Oblita Therapeutics ...

AstraZeneca Plc

Bayer AG

Daiichi Sankyo Co Ltd

Eisai Co Ltd

Evotec AG

GlaxoSmithKline Plc

Grupo Praxis Pharmaceutical SA

Kancera AB

Novartis AG

Oblita Therapeutics BVBA

Sanofi

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chagas Disease (American Trypanosomiasis) - Overview

Chagas Disease (American Trypanosomiasis) - Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chagas Disease (American Trypanosomiasis) - Overview

Chagas Disease (American Trypanosomiasis) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Bayer AG

Daiichi Sankyo Co Ltd

Eisai Co Ltd

Evotec AG

GlaxoSmithKline Plc

Grupo Praxis Pharmaceutical SA

Kancera AB

Novartis AG

Oblita Therapeutics BVBA

Sanofi

Chagas Disease (American Trypanosomiasis) - Drug Profiles

benznidazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chagas disease (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chagas disease vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chagas disease vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chagas disease vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cz-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cz-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNDI-0690 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EPLBS-1246 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EPLBS-967 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fexinidazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosravuconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNF-6702 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KAN-0441411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAO-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nifurtimox - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-114137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CYP51A1 for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for African Trypanosomiasis, Chagas Disease and Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Pex14 for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VNI - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chagas Disease (American Trypanosomiasis) - Dormant Projects

Chagas Disease (American Trypanosomiasis) - Discontinued Products

Chagas Disease (American Trypanosomiasis) - Product Development Milestones

Featured News & Press Releases

Jun 22, 2017: UTEP Scientists Awarded Patent for Chagas Disease Vaccine

Nov 15, 2016: Bayer to Fight Chagas Disease in Children

Aug 08, 2016: A single compound could treat three parasitic diseases

Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease

Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease

Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy

May 03, 2013: Funding boost for GSK’s open innovation research into diseases affecting the developing world

Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease

Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2018

Number of Products under Development by Companies, H2 2018

Number ...

List of Tables

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Chagas Disease (American Trypanosomiasis) - Pipeline by AstraZeneca Plc, H2 2018

Chagas Disease (American Trypanosomiasis) - Pipeline by Bayer AG, H2 2018

Chagas Disease (American Trypanosomiasis) - Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co Ltd, H2 2018

Chagas Disease (American Trypanosomiasis) - Pipeline by Evotec AG, H2 2018

Chagas Disease (American Trypanosomiasis) - Pipeline by GlaxoSmithKline Plc, H2 2018

Chagas Disease (American Trypanosomiasis) - Pipeline by Grupo Praxis Pharmaceutical SA, H2 2018

Chagas Disease (American Trypanosomiasis) - Pipeline by Kancera AB, H2 2018

Chagas Disease (American Trypanosomiasis) - Pipeline by Novartis AG, H2 2018

Chagas Disease (American Trypanosomiasis) - Pipeline by Oblita Therapeutics BVBA, H2 2018

Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H2 2018

Chagas Disease (American Trypanosomiasis) - Dormant Projects, H2 2018

Chagas Disease (American Trypanosomiasis) - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2018

Number of Products under Development by Companies, H2 2018

Number ...

List of Figures

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports